298 related articles for article (PubMed ID: 35278370)
1. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
2. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
3. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
4. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
5. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
[TBL] [Abstract][Full Text] [Related]
6. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
8. Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells.
Montel-Hagen A; Seet CS; Li S; Chick B; Zhu Y; Chang P; Tsai S; Sun V; Lopez S; Chen HC; He C; Chin CJ; Casero D; Crooks GM
Cell Stem Cell; 2019 Mar; 24(3):376-389.e8. PubMed ID: 30661959
[TBL] [Abstract][Full Text] [Related]
9. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
Jing R; Scarfo I; Najia MA; Lummertz da Rocha E; Han A; Sanborn M; Bingham T; Kubaczka C; Jha DK; Falchetti M; Schlaeger TM; North TE; Maus MV; Daley GQ
Cell Stem Cell; 2022 Aug; 29(8):1181-1196.e6. PubMed ID: 35931029
[TBL] [Abstract][Full Text] [Related]
10. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
11. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
12.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
13. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
14. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
15. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
16. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
17. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
18. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells.
Li S; Wang CS; Montel-Hagen A; Chen HC; Lopez S; Zhou O; Dai K; Tsai S; Satyadi W; Botero C; Wong C; Casero D; Crooks GM; Seet CS
Cell Rep; 2023 Mar; 42(3):112241. PubMed ID: 36906850
[TBL] [Abstract][Full Text] [Related]
19. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
[TBL] [Abstract][Full Text] [Related]
20. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
